Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Syfovre
Pharma
Watch out, Novartis. Apellis scores major win in kidney diseases
Empaveli showed strong efficacy in two rare kidney diseases. An Apellis exec said the result “exceeded our already high expectations."
Zoey Becker
Aug 8, 2024 2:28pm
CHMP rejects Apellis' Syfovre, says yes to Merck's Winrevair
Jun 28, 2024 11:59am
Apellis takes it slow with first Syfovre DTC campaign
May 23, 2024 4:20pm
Apellis stock price slid 10% despite 'robust' growth of Syfovre
May 8, 2024 11:30am
Apellis working through continued challenges with Syfovre launch
Feb 28, 2024 11:53am
Bristol Myers wins, Apellis loses in busy week at Europe's CHMP
Jan 26, 2024 11:36am
